Bupropion Formulations: Dosing and Safety Considerations
Dosing Schedules
- The American College of Clinical Pharmacology recommends an initial dose of 150 mg once daily for 3-4 days for the SR formulation, with a maintenance dose of 150 mg twice daily (300 mg total daily) 1
- The maximum dose for the SR formulation is 400 mg per day, and for the XL formulation, it is 450 mg per day 1
Clinical Decision-Making Between Formulations
- The American Psychiatric Association suggests choosing the SR formulation when patients need more flexible dosing due to side effects or require dose adjustments for hepatic or renal impairment, allowing for easier titration in 37.5 mg increments 1
Safety Considerations Common to Both Formulations
- The National Institute of Neurological Disorders and Stroke indicates that the maximum daily dose must not exceed 450 mg to minimize seizure risk, with both formulations being contraindicated in patients with seizure disorders 1
- The American Heart Association recommends blood pressure monitoring to avoid use in uncontrolled hypertension, as well as monitoring for neuropsychiatric adverse effects, especially in patients under 24 years 1, 2
Special Population Dosing
- For patients with renal impairment (GFR <90 mL/min), the National Kidney Foundation suggests reducing the total daily dose by half, with close monitoring required as bupropion and metabolites are cleared renally 1
- The American Geriatrics Society recommends starting older adults with 37.5 mg every morning, increasing by 37.5 mg every 3 days as tolerated, with a maximum dose of 150 mg twice daily (300 mg total) for the SR formulation 1
Common Adverse Effects
- The Journal of the American Medical Association reports that dry mouth is a common adverse effect, occurring in 20% of patients in obesity trials 2
Critical Formulation Switching Considerations
- When switching between SR and XL formulations, the FDA recommends maintaining the same total daily dose when possible, while monitoring patients closely due to historical bioequivalence issues between brand and generic formulations 1